FICHIT

Je m'inscris

ADOCIA

0/5 (0 note(s))
Note donnée : aucune
Paris
387
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes:
1. Two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 in phase 2a and BioChaperone Lispro U200 in phase 1), these formulations have been licensed to Eli Lilly (signature of a partnership in December 2014).
2. A fast-acting formulation of human insulin (HinsBet U100) in phase 2a.
3. A combination of insulin glargine and a fast-acting insulin analog (BioChaperone Combo) in phase 2a.
Besides Adocia developed a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer. This product is currently in phase 3 in India.
www.adocia.com
ADOC:FP

Fiche créée le 10/04/2016 par Guillaume   vue 8 fois.